5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial.

By S. Kapadia, M. Leon, R. Makkar, E. Tuzcu, L. Svensson, S. Kodali, J. Webb, M. Mack, P. Douglas, V. Thourani and 11 more. The Lancet, 2015

795 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/377630e401f16c8ccaa462ba15918c1b1e30dab8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “TAVR was compared with standard therapy in a prospective RCT of patients with severe symptomatic AS who were deemed inoperable (53,58,60).”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, methodology): “TAVR was compared with standard therapy in a prospective RCT of patients with severe symptomatic AS who were deemed inoperable (53,58,60).”